Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.42 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12518642 | 1.00 | MC4R (0.48) | MC4RKISS1RIL23RSMN1; SMN2MAPK1 | |
| SCHEMBL12515484 | 0.98 | MC4R (0.49) | MC4RKISS1RIL23RSMN1; SMN2MAPK1 | |
| SCHEMBL12515468 | 0.98 | MC4R (0.49) | MC4RKISS1RIL23RSMN1; SMN2MAPK1 | |
| SCHEMBL12515480 | 0.98 | MC4R (0.49) | MC4RKISS1RIL23RSMN1; SMN2MAPK1 | |
| SCHEMBL12514979 | 0.98 | MC4R (0.49) | MC4RKISS1RIL23RSMN1; SMN2MAPK1 | |
| SCHEMBL19445738 | 0.97 | MC4R (0.48) | MC4RIL23RPRKACBCCKBR | |
| SCHEMBL13978375 | 0.95 | MC4R (0.47) | MC4RKISS1RIL23R | |
| SCHEMBL12515001 | 0.95 | MC4R (0.47) | MC4RKISS1RIL23R | |
| SCHEMBL12514982 | 0.95 | MC4R (0.47) | MC4RKISS1RIL23R | |
| SCHEMBL12518602 | 0.94 | SMN1; SMN2 (0.47) | MC4RSMN1; SMN2MAPK1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-9457027-B2 | Compounds for use in treatment of mucostis | CELLCEUTIX CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-9155738-B2 | Compounds for use in treatment of mucostitis | CELLCEUTIX CORPORATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | INNOVATION PHARMACEUTICALS INC. | 2014-12-11 | — | — | US | disclosed |
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012158672-A2 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20110178104-A1 | Anti-Heparin Compounds | POLYMEDIX INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | MC4R 3911/4885KISS1R 3918/4885IL23R 623/4885 |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | MUC1, FUT6, MMP8 | MC4R 3911/4885KISS1R 3918/4885IL23R 623/4885 |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | MC4R 3911/4885KISS1R 3918/4885IL23R 623/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | MC4R 4576/4885KISS1R 4478/4885IL23R 877/4885 |
| US-20110178104-A1 | Anti-Heparin Compounds | SERPINC1, CFH, SERPINH1 | MC4R 1375/4885KISS1R 1469/4885IL23R 3509/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | MC4R 4576/4885KISS1R 4478/4885IL23R 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.